Wednesday January 17th 2018

Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment

CLARITY Extension data published in the MS Journal shows 75% of patients who received 2 annual short courses of Mavenclad (Cladribine Tablets) remained relapse free over 4 years The majority of patients who experienced Grade 3 lymphopenia in Years 1 and… Biopharmaceuticals, Neurology Merck, MAVENCLAD, Cladribine, multiple sclerosis (Source: HSMN NewsFeed)

Source¬†–¬†

Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment

Leave a Comment

More from category

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS
FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]